Skip to main content
Erschienen in: AIDS and Behavior 4/2015

01.04.2015 | Original Paper

Comparison of Pharmacy-Based Measures of Adherence to Antiretroviral Therapy as Predictors of Virological Failure

verfasst von: Cassidy E. Henegar, Daniel Westreich, Mhairi Maskew, M. Alan Brookhart, William C. Miller, Pappie Majuba, Annelies Van Rie

Erschienen in: AIDS and Behavior | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

We compared multiple pharmacy refill-based adherence indicators for antiretroviral therapy, as well as thresholds for defining non-adherent behavior, based on ability to predict virological failure. A total of 29,937 pharmacy visits with corresponding viral load assessments were contributed by 8,695 patients attending a large clinic in Johannesburg, South Africa. Indicators based on pill coverage and timing of refill pickup performed comparably using the strictest thresholds for adherence [100 % pill coverage: odds ratio (OR) (95 % confidence interval (CI)) : 1.26 (1.15, 1.39); prescription picked up on or before scheduled refill date: 1.27 (1.16,1.38)]. For both types of indicators, the association between non-adherence and virological failure increased as the threshold defining adherent behavior was lowered. All measures demonstrated high specificity (range 84–98 %), but low sensitivity (5–19 %). In this setting, patients identified as non-adherent using pharmacy-based indicators are likely correctly classified and in need of interventions to improve compliance. Pharmacy based measures alone, however, are inadequate for identifying most cases of nonadherence.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat de Garcia Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. JAIDS. 2002;30(1):105–10. de Garcia Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. JAIDS. 2002;30(1):105–10.
2.
Zurück zum Zitat Kredo T, Walt J, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane DB Syst Rev. 2009; 8(3): Article Number CD007268. Kredo T, Walt J, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane DB Syst Rev. 2009; 8(3): Article Number CD007268.
3.
Zurück zum Zitat Lima V, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–80.CrossRefPubMed Lima V, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–80.CrossRefPubMed
4.
Zurück zum Zitat Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed
5.
Zurück zum Zitat Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed
6.
Zurück zum Zitat World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva: WHO; 2006. World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva: WHO; 2006.
7.
Zurück zum Zitat McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2012;52(4):493–506.CrossRef McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2012;52(4):493–506.CrossRef
8.
Zurück zum Zitat Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4:187–91.CrossRefPubMed Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4:187–91.CrossRefPubMed
9.
Zurück zum Zitat Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–8.CrossRefPubMed Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–8.CrossRefPubMed
10.
Zurück zum Zitat Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.CrossRefPubMed Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.CrossRefPubMed
11.
Zurück zum Zitat Fox M, Maskew M, Macphail AP, et al. Cohort profile: the Themba Lethu Clinical cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42(2):430–9.CrossRefPubMedCentralPubMed Fox M, Maskew M, Macphail AP, et al. Cohort profile: the Themba Lethu Clinical cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42(2):430–9.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS ONE. 2011;6(8):e22778.CrossRefPubMedCentralPubMed Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS ONE. 2011;6(8):e22778.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.CrossRefPubMed Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.CrossRefPubMed
14.
Zurück zum Zitat Riddler S, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–106.CrossRefPubMed Riddler S, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–106.CrossRefPubMed
15.
Zurück zum Zitat Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T. The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 2011;20(3):317–20.CrossRefPubMedCentralPubMed Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T. The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 2011;20(3):317–20.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa- a prospective cohort study. BMC Public Health. 2011;11:88.CrossRefPubMedCentralPubMed El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa- a prospective cohort study. BMC Public Health. 2011;11:88.CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–87.CrossRefPubMedCentralPubMed El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–87.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10:42.CrossRefPubMedCentralPubMed Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10:42.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–94.CrossRefPubMed Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–94.CrossRefPubMed
20.
Zurück zum Zitat Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.CrossRef Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.CrossRef
21.
Zurück zum Zitat Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882–90.CrossRefPubMed Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882–90.CrossRefPubMed
23.
Zurück zum Zitat Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.CrossRefPubMed Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.CrossRefPubMed
Metadaten
Titel
Comparison of Pharmacy-Based Measures of Adherence to Antiretroviral Therapy as Predictors of Virological Failure
verfasst von
Cassidy E. Henegar
Daniel Westreich
Mhairi Maskew
M. Alan Brookhart
William C. Miller
Pappie Majuba
Annelies Van Rie
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 4/2015
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0953-2

Weitere Artikel der Ausgabe 4/2015

AIDS and Behavior 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.